Literature DB >> 21709769

Why Do We Need ADAMTS13?

Han-Mou Tsai1.   

Abstract

Entities:  

Year:  2005        PMID： 21709769      PMCID： PMC3121331          DOI： 10.2491/jjsth.16.54

Source DB:  PubMed          Journal:  Nihon Kessen Shiketsu Gakkai shi        ISSN： 0915-7441


× No keyword cloud information.
  74 in total

1.  Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen.

Authors:  Y Asada; A Sumiyoshi; T Hayashi; J Suzumiya; K Kaketani
Journal:  Thromb Res       Date:  1985-06-01       Impact factor: 3.944

2.  Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient.

Authors:  Phuong-Thu T Pham; Gabriel M Danovitch; Alan H Wilkinson; H Albin Gritsch; Phuong-Chi T Pham; Tong M Eric; Elizabeth Kendrick; Lassman R Charles; Han-Mou Tsai
Journal:  Transplantation       Date:  2002-10-27       Impact factor: 4.939

3.  Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1.

Authors:  H M Tsai; I I Sussman; D Ginsburg; H Lankhof; J J Sixma; R L Nagel
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

4.  Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; A Li; G Rock
Journal:  Clin Lab       Date:  2001       Impact factor: 1.138

Review 5.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).

Authors:  Christoph Licht; Ludwig Stapenhorst; Thorsten Simon; Ulrich Budde; Reinhard Schneppenheim; Bernd Hoppe
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

7.  Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome.

Authors:  Masanori Matsumoto; Koichi Kokame; Kenji Soejima; Masayoshi Miura; Syuhei Hayashi; Yasuhiko Fujii; Asayuki Iwai; Etsuro Ito; Yoichiro Tsuji; Mayuko Takeda-Shitaka; Mitsuo Iwadate; Hideaki Umeyama; Hideo Yagi; Hiromichi Ishizashi; Fumiaki Banno; Tomohiro Nakagaki; Toshiyuki Miyata; Yoshihiro Fujimura
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

Review 8.  Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.

Authors:  Roslyn Yomtovian; Waldemar Niklinski; Bernard Silver; Ravindra Sarode; Han-Mou Tsai
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

9.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

Authors:  Valentina Bianchi; Rodolfo Robles; Lorenzo Alberio; Miha Furlan; Bernhard Lämmle
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

Review 10.  Shear stress and von Willebrand factor in health and disease.

Authors:  Han-Mou Tsai
Journal:  Semin Thromb Hemost       Date:  2003-10       Impact factor: 4.180
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.